Eidogen-Sertanty Licenses Discovery Informatics Software and Databases to Cephalon
Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today that Cephalon, Inc. (Nasdaq:CEPH), a Pennsylvania-based biopharmaceutical company, will access Eidogen-Sertanty’s Kinase Knowledgebase (KKB(TM)), Target Informatics Platform(TM) (TIP(TM)), and EVE(TM) Comparative Visualization software.
Scientists at Cephalon will use the proprietary software to support small molecule drug discovery projects in their neurology and oncology therapeutic programs.
“We are pleased to provide Cephalon with broad access to several of our discovery informatics products. We’re confident that our kinase informatics and structural informatics solutions will help the experienced research team at Cephalon accelerate their lead discovery efforts,” said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately-held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty’s unique and powerful suite of software, databases and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com .
Eidogen-Sertanty, the Eidogen-Sertanty logo, DirectDesign, Kinase Knowledgebase, EVE, and Target Informatics Platform are trademarks of Eidogen-Sertanty, Inc.
All other trademarks in this release are the property of their respective owners.
